The cost of Gazyva (obinutuzumab) can vary significantly depending on factors such as insurance coverage, geographic location, and the specific dosage and treatment regimen prescribed by a healthcare professional. The drug is typically administered intravenously, and the overall cost includes not only the medication itself but also the associated infusion services.
How much does Gazyva cost without insurance?
Without insurance, the list price for a single vial of Gazyva can be several thousand dollars. For instance, a 100 mg/10 mL vial might be priced around $3,800, and a 1000 mg/10 mL vial could be in the range of $38,000 [1]. A full course of treatment, which may involve multiple infusions over time, can therefore accumulate to a substantial cost.
What financial assistance programs are available for Gazyva?
To help patients manage the expense of Gazyva, Genentech, the manufacturer, offers a program called Genentech Access to Care. This program provides financial assistance for eligible commercially insured patients, potentially reducing out-of-pocket costs to as low as $0 for infusions and $25 for medication under certain conditions [1]. Patient assistance programs from foundations or disease-specific organizations may also offer support.
When does Gazyva's patent expire?
The patent expiry dates for Gazyva are complex due to multiple patents covering different aspects of the drug, including its composition of matter, manufacturing processes, and methods of use. Information regarding specific patent expiry timelines and any ongoing patent challenges can be found on resources like DrugPatentWatch.com [2]. Patent expirations are critical for the potential entry of biosimilar versions, which could impact future pricing.
How does Gazyva's cost compare to other similar treatments?
Gazyva is a targeted therapy used in the treatment of certain types of leukemia and lymphoma. Its cost is generally in line with other biologic cancer therapies, which are often expensive due to the complexity of their development and manufacturing. Comparisons with other CD20-directed monoclonal antibodies, such as rituximab, may reveal differences in acquisition costs and the total cost of care, considering factors like infusion frequency and efficacy.
What factors influence the price of Gazyva?
The price of Gazyva is influenced by research and development costs, manufacturing expenses, clinical trial investments, and market demand. Regulatory approvals and the drug's therapeutic value also play a role. As with many specialty pharmaceuticals, pricing strategies are designed to recoup investment and fund ongoing innovation.